tiprankstipranks
Aptose Biosciences Launches TUSCANY Study for AML
Company Announcements

Aptose Biosciences Launches TUSCANY Study for AML

Story Highlights

Aptose Biosciences (TSE:APS) has released an update.

Don't Miss our Black Friday Offers:

Aptose Biosciences has launched the TUSCANY Phase 1/2 study to test a new triplet therapy for newly diagnosed acute myeloid leukemia (AML) patients. This innovative treatment combines tuspetinib with azacitidine and venetoclax, aiming to offer an effective frontline therapy for AML patients who cannot undergo intensive chemotherapy. The trial is being conducted across several sites in the United States, with potential to impact a broad range of AML cases.

For further insights into TSE:APS stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAptose Biosciences Announces $8 Million Public Offering
TheFlyAptose Biosciences to sell 40M shares at 20c in public offering
TheFlyAptose Biosciences price target lowered to $2 from $7 at H.C. Wainwright
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App